LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Slēgts

32.5 1.56

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

30.89

Max

33.58

Galvenie mērījumi
By Trading Economics
Ienākumi	10M -177K
Pārdošana	5.7M 104M
Peļņas marža	-0.171
Darbinieki	493
EBITDA	19M 4.1M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+103.56% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	32M 1.7B
Iepriekšējā atvēršanas cena	30.94
Iepriekšējā slēgšanas cena	32.5

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2026. g. 2. marts 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2026. g. 2. marts 23:26 UTC

Galvenie ziņu notikumi

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2026. g. 2. marts 22:41 UTC

Tirgus saruna

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2026. g. 2. marts 22:32 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 22:32 UTC

Tirgus saruna

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2026. g. 2. marts 22:21 UTC

Tirgus saruna

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2026. g. 2. marts 22:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. marts 22:11 UTC

Tirgus saruna

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2026. g. 2. marts 22:10 UTC

Iegādes, apvienošanās, pārņemšana

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2026. g. 2. marts 22:06 UTC

Tirgus saruna

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2026. g. 2. marts 22:00 UTC

Tirgus saruna

Peļņas

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 22:00 UTC

Tirgus saruna

Peļņas

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 2. marts 21:35 UTC

Iegādes, apvienošanās, pārņemšana

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2026. g. 2. marts 21:34 UTC

Iegādes, apvienošanās, pārņemšana

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2026. g. 2. marts 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026. g. 2. marts 21:17 UTC

Galvenie ziņu notikumi

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2026. g. 2. marts 20:44 UTC

Peļņas

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026. g. 2. marts 20:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2026. g. 2. marts 20:28 UTC

Peļņas

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2026. g. 2. marts 20:25 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2026. g. 2. marts 20:24 UTC

Peļņas

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026. g. 2. marts 20:14 UTC

Iegādes, apvienošanās, pārņemšana

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026. g. 2. marts 20:12 UTC

Galvenie ziņu notikumi

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2026. g. 2. marts 20:08 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 20:08 UTC

Tirgus saruna

Galvenie ziņu notikumi

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2026. g. 2. marts 20:05 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

103.56% augšup

Prognoze 12 mēnešiem

Vidējais 65.75 USD 103.56%

Augstākais 100 USD

Zemākais 38 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.